Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ponatinib + Mini-hyper CVD + Venetoclax in R/R T-cell ALL
NCT05268003Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jun 2022
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ponatinib in t-cell acute lymphoblastic leukemia (T-ALL), sponsored by University of Texas MD Anderson Cancer Center. Started Jun 2022; status: terminated.
02
Drugs
ponatinib
03
Conditions
t-cell acute lymphoblastic leukemia (T-ALL)
Beyond the preview
Go deeper on NCT05268003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05268003.